Retatutride

Retatutride - 40mg Pen 

Availability:In Stock
Brand:Meytrix 
Product Code:Ret30

Retatrutide 40mg is a GLP-1, GIP, and glucagon metabolic-support weight-management product designed to support appetite control, satiety, food-intake regulation, metabolic support, energy-use support, and progressive body-composition improvement.

Retatrutide works around GLP-1, GIP, and glucagon metabolic-support pathways, making it the advanced option in Meytrix Therapeutics weight-management range for structured fat-loss and body-composition protocols.

This product includes one Retatrutide 40mg reconstituted for use in the Meytrix Therapeuticals reusable or disposable pen system. It is intended for structured once-weekly dosing, with gradual escalation based on tolerance and response.

Each Pen includes:

  • 1 x Retatrutide 40mg Peptide Pen 
  • 8 x pen needles

This product is supplied in a disposable pen l. The reusable pen kit is sold separately.

How It Works

Retatrutide is positioned as the strongest metabolic-support option in the Meytrix Therapeutics weight-management range, using triple-pathway support for appetite regulation, satiety, food-intake control, metabolic signalling, and energy-use support.

Its activity is positioned around three key metabolic-support pathways involved in hunger control, fullness after meals, metabolic regulation, and energy expenditure.

Primary Support Areas

  • Appetite control: supports reduced hunger and food cravings.
  • Satiety support: supports improved fullness after meals.
  • Food-intake control: supports lower calorie intake through improved hunger regulation.
  • Metabolic support: supports structured fat-loss progression over time.
  • Energy-use support: supports increased energy expenditure and body-composition improvement.

Retatrutide is a metabolic-regulation protocol. It is not a structural repair peptide.

Results and Outcomes

Retatrutide is used where the objective is stronger appetite control, improved dietary consistency, and more reliable fat-loss progress over time.

It may be used as part of protocols focused on:

  • Reduced hunger
  • Improved satiety
  • Lower food intake
  • Better dietary control
  • Metabolic regulation
  • Stronger fat-loss support
  • Progressive weight-management support
  • Body-composition improvement over time

Expected Outcomes

Expected Outcome Practical Effect
Reduced appetite Supports less hunger through the day.
Improved satiety Supports easier portion control.
Lower food intake Supports improved calorie control.
Better dietary adherence Supports improved consistency with a structured eating plan.
Progressive fat-loss support Supports ongoing body-composition improvement over time.

Dosage Protocol

Product Format

  • Product contents: 1 x Retatrutide Pen 40mg
  • Needles included: 8 x pen needle
  • Reusable pen kit: sold separately

Per Cartridge

  • Strength: 40mg / 3mL
  • Concentration: 15mg/mL
  • Pen system: 200 clicks per cartridge
  • Per click: 0.15mg
  • Per click volume: 0.01mL
  • Administration: once weekly unless using the higher split-dose format

Click Calculation

  • 40mg ÷ 3mL = 15mg/mL
  • 40mg ÷ 200 clicks = 0.15mg per click
  • 3mL ÷ 200 clicks = 0.01mL per click

Dose Reference

Clicks Dose Volume Use
5 clicks 0.75mg 0.05mL Low reference dose
10 clicks 1.5mg 0.10mL Weeks 1–4
15 clicks 2.25mg 0.15mL Intermediate reference dose
20 clicks 3.0mg 0.20mL Weeks 5–8
25 clicks 3.75mg 0.25mL Intermediate reference dose
30 clicks 4.5mg 0.30mL Weeks 9–12
35 clicks 5.25mg 0.35mL Split-dose reference
40 clicks 6.0mg 0.40mL Weeks 13–16
50 clicks 7.5mg 0.50mL Maintenance reference
60 clicks 9.0mg 0.60mL Higher-range reference

Escalated Split-Dose Reference

Schedule Total Weekly Clicks Total Weekly Dose Total Weekly Volume
35 clicks twice weekly 70 clicks 10.5mg 0.70mL
40 clicks twice weekly 80 clicks 12.0mg 0.80mL

Recommended Dosage

Retatrutide Refill Cartridge 40mg is administered once weekly unless using the higher split-dose format.

Phase Frequency Clicks Dose Volume
Weeks 1–4 Once weekly 10 clicks 1.5mg 0.10mL
Weeks 5–8 Once weekly 20 clicks 3.0mg 0.20mL
Weeks 9–12 Once weekly 30 clicks 4.5mg 0.30mL
Weeks 13–16 Once weekly 40 clicks 6.0mg 0.40mL
Maintenance reference Once weekly 50 clicks 7.5mg 0.50mL
Higher-range reference Once weekly 60 clicks 9.0mg 0.60mL
Higher split-dose option Twice weekly 35 clicks per dose 10.5mg total weekly 0.70mL total weekly
Maximum split-dose option Twice weekly 40 clicks per dose 12.0mg total weekly 0.80mL total weekly

Cycle Structure

  • Use once weekly according to the structured escalation protocol.
  • Do not inject more than once weekly unless using the higher split-dose format.
  • At higher ranges, split the weekly dose evenly into twice-weekly administrations.
  • Do not increase the dose if the current dose is not well tolerated.
  • Dose escalation should be gradual and based on tolerance.
  • Use as part of a structured weight-management plan that includes dietary control, hydration, and consistent lifestyle habits.
  • A 50-click dose is commonly used as a practical maintenance reference because it provides approximately 6 weeks of treatment from one cartridge.
  • Some users may require a lower or higher maintenance reference depending on response, tolerance, and weight-management goals.

Notes

  • This product is a single refill pen cartridge.
  • Product includes 1 x Retatrutide 40mg refill pen cartridge and 8 x pen needle.
  • Reusable pen kit is sold separately.
  • Store refrigerated at 2–8°C.
  • Do not freeze.
  • Administer subcutaneously using the Meytrix pen system.
  • Common administration areas include the abdomen, thigh, or upper arm.
  • Rotate administration sites.
  • Use once weekly unless following the higher split-dose format.
  • Higher doses should only be used once lower doses are well tolerated.
  • Retatrutide Refill Cartridge Pen 40mg is the single-cartridge format in Meytrix Therapeutics weight-management range.
  • Retatrutide is a metabolic-regulation protocol and is not a structural repair peptide.

Warnings

  • Not suitable for people under the age of 18.
  • Not suitable during pregnancy.
  • Not suitable while breastfeeding.